Volume Spike Investor

InterMune Inc. (NASDAQ: ITMN) is soaring with more than a double on key news of its EMA recommendation of market ing approval in its idiopathic pulmonary fibrosis drug called Esbriet (pirfenidone).  The full news and analysis is available at BioHealthInvestor.com in the quest for potential ten-baggers. What traders need to know is that at 10:20 [...]